Arcutis Biotherapeutics, Inc.
For the period ended Sep 30, 2025. Filed Oct 28, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 28, 2025
ARQT$26.20+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and par value)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $47,120 | $71,335 |
| Restricted cash | 308 | 617 |
| Marketable securities | 143,948 | 156,620 |
| Trade receivables, net | 115,116 | 73,066 |
| Inventories | 22,419 | 14,526 |
| Prepaid expenses and other current assets | 20,313 | 19,656 |
| Total current assets | 349,224 | 335,820 |
| Property, plant, and equipment, net | 1,215 | 1,041 |
| Intangible assets, net | 15,375 | 9,479 |
| Operating lease right-of-use asset | 4,567 | 1,953 |
| Other assets | 596 | 596 |
| Total assets | $370,977 | $348,889 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $5,795 | $14,220 |
| Current portion of long-term debt, net | 1,000 | — |
| Accrued and other current liabilities | 92,975 | 66,793 |
| Total current liabilities | 99,770 | 81,013 |
| Operating lease liability, long-term | 5,276 | 2,562 |
| Long-term debt, net | 107,498 | 107,203 |
| Other long-term liabilities | 360 | 570 |
| Total liabilities | 212,904 | 191,348 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at September 30, 2025 and December 31, 2024; 120,288,146 and 117,848,033 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 12 | 12 |
| Additional paid-in capital | 1,313,602 | 1,279,479 |
| Accumulated other comprehensive loss | (62) | (7) |
| Accumulated deficit | (1,155,479) | (1,121,943) |
| Total stockholders’ equity | 158,073 | 157,541 |
| Total liabilities and stockholders’ equity | $370,977 | $348,889 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.